Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of biphenyl compound 4-(3', 4'-dihydroxy phenyl) cinnamic acid in drug preparation

A technology of dihydroxyphenyl and compounds, applied in the field of medicine, can solve problems that have not yet been seen

Active Publication Date: 2016-04-13
FUDAN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] There is no anti-HBV effect of the biphenyl compound 4-(3',4'-dihydroxyphenyl)cinnamic acid involved in the present invention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of biphenyl compound 4-(3', 4'-dihydroxy phenyl) cinnamic acid in drug preparation
  • Application of biphenyl compound 4-(3', 4'-dihydroxy phenyl) cinnamic acid in drug preparation
  • Application of biphenyl compound 4-(3', 4'-dihydroxy phenyl) cinnamic acid in drug preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0017] Example preparation of 14-(3',4'-dihydroxyphenyl) cinnamic acid

[0018] Take 25kg of dry roots of Sesame chinensis, crush them, and reflux extract with 95% ethanol for 3 times (50L×3), each time for 2h, combine the extracts and concentrate to obtain 0.95kg of extract, add water (4L) to suspend, and add an equal volume of petroleum Extracted 5 times with ether, ethyl acetate and n-butanol, combined the extracts and concentrated to dryness to obtain 200 g of ethyl acetate extract. The ethyl acetate extraction part was separated by silica gel (200-300 mesh) column chromatography, and sequentially eluted with dichloromethane-methanol (50:1-0:1) gradient to obtain 11 fractions (Fr.1-11) , wherein the fraction Fr.3 (32g) was subjected to silica gel column chromatography (dichloromethane-methanol, 30:1, 20:1, 10:1, 5:1, 3:1, 1:1), MPLC (methanol -water, 20:80-80:20 gradient elution) and semi-preparative HPLC and other means to purify, isolate and obtain compound 4-(3',4'-dih...

Embodiment 2

[0020] Embodiment 2 in vitro anti-HBV experiment

[0021] 2.2.15 cell line of HepG2 (Ministry of Education / Ministry of Health Key Laboratory of Medical Molecular Virology, Shanghai), with 10×10 cells per well 5 Cells were inoculated in a 24-well plate, the medium was DMEM, the growth medium contained 10% fetal bovine serum, 380 μg / ml G418, 0.03% glutamine, 100 μg / ml each of penicillin and streptomycin, in 5% CO 2 Cultivate in an incubator at 37°C. After 48 hours, replace it with a drug-containing culture solution aided by dimethyl sulfoxide. Set 3 to 5 concentrations for each drug, and set 4 parallel wells for each concentration, and continue to cultivate for 9 days. (Change the medium once every 3 days), collect the supernatant and detect the content of HBsAg and HBeAg by ELISA. Under the same conditions, the culture supernatant without drugs was used as the control group. At the same time, the above cell lines were used to measure the cytotoxicity of the drug by MTT method...

Embodiment 3

[0025] Example 3 Anti-complement classical pathway activation test in vitro

[0026] Take 0.04ml of complement (guinea pig serum), add barbiturate buffer solution (BBS) to prepare a 1:10 solution, and double-dilute with BBS to 1:20, 1:40, 1:80, 1:160, 1:10 320, 1:640 and 1:1280 solutions. Take 1:1000 hemolysin, 0.1ml of 2% sheep red blood cells (SRBC) and 0.2ml of complement of each concentration, dissolve them in 0.2ml of BBS, mix well, put them in a low-temperature high-speed centrifuge at 4000rpm and 4℃ Centrifuge for 5min. Take 0.2ml of the supernatant from each tube and place it in a 96-well plate, and measure its absorbance at 405nm. At the same time, a complete hemolysis group (0.1ml 2% SRBC, 0.1ml hemolysin dissolved in 0.4ml triple distilled water) was set up in the experiment. The absorbance of three-distilled water lysed blood vessels was used as the standard of total hemolysis, and the hemolysis rate was calculated. Plot the dilution of complement on the X-axis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicine and relates to application of biphenyl compound 4-(3', 4'-dihydroxy phenyl) cinnamic acid in preparation of anti-HBV and anticomplement drug. One biphenyl compound is separated from dried root of helicteres angustifolia, experiments prove that the biphenyl compound has strong anti-HBV activity, effective concentration is low, IC50 value on HBsAg is 18.4 micrograms / ml which is significantly higher than positive control lamivudine, and suppression ratio on HBeAg is 34.5% when the maximum acellular toxicity concentration is 50 micrograms / ml; in addition, in-vitro anticomplement activity measurement results show that the biphenyl compound has strong inhibition effect on complement system canonical pathway and alternative pathway complement activation, the CH50 value on canonical pathway complement activation is 0.0022mg / ml, and the AP50 value on alternative pathway activation is 0.0057mg / ml. The compound can be further used for preparing anti-HBV drugs and anticomplement drugs.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the use of a biphenyl compound 4-(3',4'-dihydroxyphenyl)cinnamic acid isolated from the medicinal plant Sesame chinensis in pharmacy, especially in the preparation of anti-inflammatory drugs. Use in hepatitis B virus drugs and anti-complement drugs. Background technique [0002] According to relevant statistics, there are about 300 million people in the world who are chronic hepatitis B virus (HBV) carriers, and my country accounts for about half of them. Hepatitis B virus infection has become one of the major diseases affecting human health globally. Since HBV infection can lead to chronic hepatitis, cirrhosis and primary liver cancer, it has become one of the nine major diseases affecting human life. Since the relative risk rate of liver cancer among chronic HBV-infected persons compared with non-carriers is 217, about 2 million people die from liver cirrhosis and liver cancer caused by ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/192A61P1/16A61P31/20C07C51/42C07C59/52
Inventor 陈道峰殷翔史训龙朱海燕卢燕
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com